

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Committee on Vital and Health Statistics: Meeting

Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) announces the following advisory committee meeting.

Name: National Committee on Vital and Health Statistics (NCVHS), Full Committee Meeting.

Date and Times: Thursday, September 13, 2018: 9:00 a.m.–5:00 p.m. (EDT); Friday, September 14, 2018: 8:30 a.m.–3:00 p.m. (EDT).

Place: Melrose Georgetown Hotel, 2430 Pennsylvania Avenue NW, Washington, DC 20037.

Status: Open.

Purpose: At the September 13–14, 2018 meeting, the Committee will hear presentations, hold discussions on several health data policy topics and continue work on projects outlined in the NCVHS 2018 workplan. Anticipated action items during this meeting include an Environmental Scan Report on Health Terminologies and Vocabularies (T/V); and a summary report of the health T/V expert roundtable meeting held July 17–18, 2018. The NCVHS Population Health Subcommittee will hold a session with panelists to provide input to the Committee regarding strategies and resources/tools to increase access to small area data, and in general, the challenges in making relevant sub-national level health data more readily available. Subcommittee activities for discussion include the Predictability Roadmap as part of the Standards Subcommittee's project to identify possible approaches to improve predictability and improvements in the adoption and processes related to updating standards and operating rules for electronic administrative transactions (e.g., claims, eligibility, electronic funds transfer). The Privacy, Confidentiality & Security Subcommittee will continue its focus on use cases that highlight the intersection of the regulated and unregulated domains for its "Health Information Privacy and Security Beyond HIPAA" project, and will propose a model that depicts the opportunities to address risks to individually identifiable information through improved stewardship for consideration by the full Committee.

The Committee will initiate discussion regarding plans for the NCVHS Thirteenth Report to Congress. The agenda times and topics are subject to change. There will be a public

comment period on both meeting days. Please refer to the posted agenda for any updates.

Contact Persons for More Information: Substantive program information may be obtained from Rebecca Hines, MHS, Executive Secretary, NCVHS, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Hyattsville, Maryland 20782, telephone (301) 458–4715. Summaries of meetings and a roster of Committee members are available on the home page of the NCVHS website: www.ncvhs.hhs.gov, where further information including an agenda and instructions to access the audio broadcast of the meetings will be posted.

Should you require reasonable accommodation, please contact the CDC Office of Equal Employment Opportunity on (770) 488–3210 as soon as possible.

Dated: July 25, 2018.

Laina Bush,

Deputy Assistant Secretary for Planning and Evaluation, Office of the Assistant Secretary for Planning and Evaluation.

[FR Doc. 2018–16361 Filed 7–30–18; 8:45 am]

BILLING CODE 4151–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Emergency Use of Treatment for Uncontrolled Hemorrhage Due to Agents of Military Combat; Correction

AGENCY: Office of the Secretary, Department of Health and Human Services.

ACTION: Notice, correction.

SUMMARY: The Department of Health and Human Services is correcting a notice that appeared in the **Federal Register** on July 16, 2018. The notice announced the Secretary's Declaration Regarding Emergency Use of Treatment for Uncontrolled Hemorrhage During an Emergency Involving Agents of Military Combat pursuant to section 564 of the Federal Food, Drug & Cosmetic (FD&C) Act. On July 9, 2018, the Secretary declared that circumstances exist justifying the authorization of emergency use of freeze dried plasma (FDP) for the treatment of hemorrhage or coagulopathy during an emergency involving agents of military combat (e.g., firearms, projectiles, and explosive devices) when plasma is not available for use or when the use of plasma is not practical, pursuant to section 564 of the FD&C Act, subject to the terms of any authorization issued under that section. This notice is correcting the July 16,

2018 notice to correctly state the Secretary's declaration.

FOR FURTHER INFORMATION CONTACT: Robert P. Kadlec, MD, MTM&H, MS, Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, 200 Independence Avenue SW, Washington, DC 20201, Telephone (202) 205–2882 (this is not a toll free number).

SUPPLEMENTARY INFORMATION: In the **Federal Register** of July 16, 2018 (83 FR 32884) appearing on page 32884 in FR Doc. 2018–15152 the following corrections are made:

1. Title, change the title of the notice to "Declaration Regarding Emergency Use of Treatment for Hemorrhage or Coagulopathy During an Emergency Involving Agents of Military Combat."

2. Summary section, change the second paragraph to: "On the basis of this determination, on July 9, 2018, the Secretary declared that circumstances exist justifying the authorization of emergency use of freeze dried plasma (FDP) for the treatment of hemorrhage or coagulopathy during an emergency involving agents of military combat (e.g., firearms, projectiles, and explosive devices) when plasma is not available for use or when the use of plasma is not practical, pursuant to section 564 of the FD&C Act, subject to the terms of any authorization issued under that section."

3. **SUPPLEMENTARY INFORMATION** section, subpart I, Background, second paragraph second sentence, delete "French" before "FDP."

4. **SUPPLEMENTARY INFORMATION** section, subpart III, Determination of the Secretary of Health and Human Services, change paragraph 1 to: "On July 9, 2018, on the basis of the Deputy Secretary of Defense's determination that there is a military emergency or significant potential for a military emergency involving a heightened risk to U.S. military forces of an attack with an agent or agents that may cause, or are otherwise associated with an imminently life-threatening and specific risk to those forces, I declared that circumstances exist justifying the authorization of emergency use of FDP for the treatment of hemorrhage or coagulopathy during an emergency involving agents of military combat (e.g., firearms, projectiles, and explosive devices) when plasma is not available for use or when the use of plasma is not practical, pursuant to section 564 of the FD&C Act, subject to the terms of any authorization issued under that section."